Alpelisib

Alpelisib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Malignant Solid Neoplasm、Anatomic Stage III Breast Cancer AJCC v8、Anatomic Stage IV Breast Cancer AJCC v8、Locally Advanced Malignant Solid Neoplasm。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Alpelisib 研究

• A Post Marketing Surveillance on Piqray in Korea

  不适用招募中South KoreaNCT05293470

• Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

  II 期招募中South KoreaNCT06837792

• First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

  I 期招募中美国NCT05627960

• Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

  II 期招募中法国NCT05577754

• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时法国德国NCT05768139

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  III 期招募中美国Argentina澳大利亚比利时NCT05646862

• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国中国NCT06993844

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  II 期招募中美国Puerto RicoNCT05564377

• 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

  II 期招募中美国NCT07543822

• EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

  不适用招募中IsraelNCT07646171

• A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

  早期 I 期招募中IsraelNCT05753657

• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

  II 期招募中美国NCT05660083

• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

  II 期招募中中国NCT06739395

• Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  II 期 / III 期招募中美国Argentina澳大利亚比利时NCT05948943

• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

  I 期招募中美国NCT06545682

• EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

  II 期招募中美国澳大利亚奥地利比利时NCT06997588

• The Drug Rediscovery Protocol (DRUP Trial)

  II 期招募中荷兰NCT02925234

• Human Models of Selective Insulin Resistance: Alpelisib, Part I

  I 期招募中美国NCT06354088

• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

  II 期招募中美国NCT05933395

• Improving Public Cancer Care by Implementing Precision Medicine in Norway

  II 期招募中挪威NCT04817956

• Alpelisib Challenge Test (ACT)

  I 期招募中美国NCT07778524

• A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

  II 期招募中澳大利亚NCT05983159

• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

  II 期招募中中国NCT06145308

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。